Sonidegib monotherapy (locally advanced BCC)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-SONIDEGIB |
|---|
| ID | REG-SONIDEGIB-BCC |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-SKIN-2025 |
Notes
BOLT trial (Migden 2015): 200 mg once daily — ORR ~58% in laBCC at 30-month update; FDA-approved for locally advanced BCC only (not mBCC). Very long half-life (~28 days) requires extended contraception counseling (20 months post-dose for females, 8 months for males). Rhabdomyolysis is rare but serious — CK monitoring protocol needed.
Used By
Indication
IND-BCC-1L-SONIDEGIB- IND-BCC-1L-SONIDEGIB